Summit Therapeutics Increases Increase to 2.0 Billion Shares of Common Stock
Summit Therapeutics amended its charter to increase the number of authorized shares of common stock to 2.0 billion from 1.0 billion, approved by stockholders on November 4, 2026. This increase provides greater flexibility for the company's financing and future execution of its strategic plans.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed